Mankind Pharma Limited

MANKIND

INE634S01028

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 04:35:04 06/02/2026 pm IST			5-day change	1st Jan Change
2,060.20 ^INR	-0.97%		-3.00%	-6.21%

04/02	IIFL Downgrades Mankind Pharma to Add from Buy, Price Target is INR2,300	MT
03/02	Mankind Pharma Limited, Q3 2026 Earnings Call, Feb 03, 2026

Mankind Pharma To Incorporate Wholly Owned Subsidiary In Russia

Published on 04/14/2025 at 05:47 pm IST

Reuters

Latest news about Mankind Pharma Limited

04/02	IIFL Downgrades Mankind Pharma to Add from Buy, Price Target is INR2,300	MT
03/02	Mankind Pharma Limited, Q3 2026 Earnings Call, Feb 03, 2026
03/02	Mankind Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025	CI
03/02	Indian drugmaker Mankind Pharma posts higher quarterly profit on strong chronic drugs demand	RE
03/02	Mankind Pharma Q3 consol net profit 4.09 billion rupees	RE
10/12	Mankind Pharma receives tax penalty of 153.2 million rupees	RE
01/12	EQT Shows Interest in Vitabiotics - ET	FW
07/11	India's Torrent Pharma posts profit boost on strong demand for chronic illness drugs	RE
07/11	Jefferies Adjusts Mankind Pharma's Price Target to INR3,000 From INR3,100, Keeps at Buy	MT
07/11	India stock benchmarks may open flat as profit-taking to offset trade optimism	RE
06/11	Bliss GVS Pharma Limited Appoints Shreekrushna Joshi as Head - Legal as Senior Management Personnel, Effective November 6, 2025	CI
06/11	Mankind Pharma Limited, Q2 2026 Earnings Call, Nov 06, 2025
06/11	Mankind Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025	CI
06/11	Mankind Pharma posts fourth straight quarterly profit fall on sales hit from tax cuts	RE
06/11	Mankind Pharma Q2 consol net profit 5.12 billion rupees	RE
10/25/10	Mankind Pharma says business transfer agreement between co, Bharat Serums & Vaccines	RE
04/25/04	Reactions after India cuts consumption tax on hundreds of items	RE
04/25/04	Reactions after India cuts consumption tax on hundreds of items	RE
19/25/19	Mankind Pharma Limited Announces Incorporation of Wholly Owned Subsidiary Company in Russia	CI
19/25/19	Mankind Pharma says wholly owned subsidiary has been incorporated in Russia	RE
07/25/07	Mankind Pharma Limited - Shareholder/Analyst Call
04/25/04	Jefferies Adjusts Mankind Pharma's Price Target to INR3,100 From INR3,000, Keeps at Buy	MT
01/25/01	Mankind Pharma Limited, Q1 2026 Earnings Call, Aug 01, 2025
31/25/31	Mankind Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2025	CI
31/25/31	India's Mankind Pharma posts lower quarterly profit as costs surge	RE

Mankind Pharma Limited is an India-based pharmaceutical company. It is engaged in developing, manufacturing, and marketing a range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It offers healthcare solutions for a range of healthcare needs with a portfolio that includes anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/ central nervous system, vitamins, minerals and nutrients and respiratory therapies. Its portfolio of brands includes Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, Monticope, Dynaglipt, and others. Its branded product portfolio spans womenâ€™s health, fertility and critical care, with several brands in their respective therapy areas. Its subsidiaries include Lifestar Pharma Private Limited, Magnet Labs Private Limited, Jaspack Industries Private Limited, and others.

Employees

19,620

Sector

Pharmaceuticals

Calendar

09/02 - Systematix India Flagship Conference

More about the company